Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting

Novartis Pharmaceuticals302 enrolled

Overview

The primary purpose of the study was to describe the tolerability of treatment with the optimal dose of LCZ696 (97 mg sacubitril / 103 mg valsartan bid), over six (6) months, in patients with heart failure with reduced ejection fraction (HFrEF) in Canada. The study was also to describe the overall tolerability, effectiveness and safety of LCZ696 for the management of HFrEF over 12 months of treatment, as well as describe the patterns of LCZ696 up and down dose titrations occurring during the management of patients with HFrEF.

Study Type

INTERVENTIONAL

Allocation

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

302

Conditions

Hearth Failure With Reduced Ejection Fraction (HFrEF)

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Key Inclusion Criteria: 1. Written informed consent must be obtained before any assessment is performed. 2. Age ≥ 18 years and ≤ 80 years. 3. Males or females. 4. Diagnosis of Heart Failure NYHA class II-III. 5. Diagnosis of Heart Failure with reduced Ejection Fraction (LVEF =\< 40%) and NYHA class II or III. 6. Stable on any dose of ACEI or ARB prior to enrolment in the study 7. Stable on any dose of a beta-blocker prior to enrolment in the study. 8. Eligible for treatment with LCZ696 as per Canadian product monograph. 9. Treated as an outpatient. 10. Signed an informed consent agreeing to participate in the study. Key Exclusion Criteria: 1. Symptomatic hypotension and/or a SBP \< 100 mmHg at baseline visit. 2. Estimated GFR \< 30 mL/min/1.73m\^2 as measured by the simplified Modification of Diet in Renal Disease (MDRD) formula at baseline visit. 3. Known history of angioedema related to previous ACEI or ARBs therapy, or history of hereditary or idiopathic angioedema. 4. Requirement of concomitant treatment with both ACEIs and ARBs. 5. Concurrent participation in other clinical trials or receiving other investigational drugs within 30 days of enrollment. 6. Hypersensitivity to the active substances, sacubitril or valsartan, or to any of the excipients. 7. Concomitant use of aliskiren-containing drugs in patients with diabetes mellitus (type 1 or type 2) or moderate to severe renal impairment (GFR \<60ml/min/1.73m\^2). 8. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes. 9. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases. 10. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test. 11. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment. Effective contraception methods are described in the protocol.

Locations (32)

Novartis Investigative Site

Edmonton, Alberta, Canada

Novartis Investigative Site

New Westminster, British Columbia, Canada

Novartis Investigative Site

Vancouver, British Columbia, Canada

Novartis Investigative Site

Winnipeg, Manitoba, Canada

Novartis Investigative Site

Moncton, New Brunswick, Canada

Outcomes

Primary Outcomes

Percentage of Participants on LCZ696 200 mg Bid at Month 6

The tolerability of LCZ696 was defined as the percentage of patients on LCZ696 at the dose of 97 mg sacubitril / 103 mg valsartan twice daily (bid) who did not experience down titration or treatment discontinuation because of adverse events while on this dose at month 6. Only descriptive analysis done.

Time frame: Month 6

Secondary Outcomes

Percentage of Participants on LCZ696 200 mg Bid at Month 12

Time frame: Month 12

Percentage of Participants Requiring Down-titration From LCZ696 200 mg

The impact of the titration scheme on the tolerability of patients maintained on LCZ696 97 mg sacubitril / 103 mg valsartan bid was defined as the percentage of patients on LCZ696 200mg requiring down-titration. Only descriptive analysis done.

Time frame: Month 12

Percentage of Participants With Down-titration Changes From LCZ696 200 mg During 12 Months of Treatment

The impact of the titration scheme on the tolerability of patients maintained on LCZ696 97 mg sacubitril / 103 mg valsartan bid was defined as the number of down-titration during the 12 months treatment period. Dow-titration schemes considered for the analysis are 200 mg to 100 mg; 100 mg to 50 mg; and 50 mg to 0 mg (i.e. treatment discontinuation). The down-titration scheme of 50mg to 0 mg was taken in account in this analysis to ensure to reflect all actual changes in dose. Only descriptive analysis done.

Time frame: Month 12

Change From Baseline in the Six Minute Walk Test (6MWT) at Month 6 and Month 12

The impact of LCZ696 on functional exercise capacity was measured by the Six Minute Walk Test at 6 and 12 months. The 6MWT measures the distance an individual is able to walf over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is able to self-pace and rest as needed as they traverse back and forth along a marked walkway. Only descriptive analysis done.

Time frame: Baseline, Month 6 and Month 12

Time to Each Up-titration to LCZ696 100 mg and LCZ696 200 mg

To describe the time of up-titration for each dose (24 mg sacubitril / 26 mg valsartan bid and 49 mg sacubitril / 51 mg valsartan bid) of LCZ696. Only descriptive analysis done.

Time frame: Baseline, Week 2, Week 4, Month 3, Month 6 and Month 12

Median Time to Reach LCZ696 200 mg

To describe the time of up-titration for each dose (24 mg sacubitril / 26 mg valsartan bid and 49 mg sacubitril / 51 mg valsartan bid) of LCZ696. Only descriptive analysis done.

Time frame: Baseline, Week 2, Week 4, Month 3, Month 6 and Month 12

Percentage of Participants on Guideline Recommended Dose of Beta-blockers and MRAs Over Time

To describe the adherence to guideline recommended dosing of beta-blockers and MRAs at 6 and 12 months of treatment of LCZ696. Only descriptive analysis done.

Time frame: Baseline, Month 6 and Month 12